adebrelimab + apatinib

Adebrelimab + apatinib is a combination therapy under investigation for the treatment of various cancers, including extensive-stage small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and HER2-negative breast cancer brain metastasis. Adebrelimab is a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor that blocks the PD-L1/PD-1 pathway to enhance anti-tumor immune responses. It features unique structural modifications for higher affinity and reduced off-target effects compared to other PD-L1 inhibitors[5][6]. Apatinib is a small molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting tumor angiogenesis. The combination aims to synergistically boost anti-tumor immunity while suppressing tumor blood vessel formation[3][4][5]. This regimen has shown promising efficacy in early-phase clinical trials for SCLC, HCC, and breast cancer brain metastases.

Brand names

AiruikaAitan

Other names

adebrelimab + apatinibSHR-1316 + YN968D1